UY37346A - Aumento de la fertilidad en especies bovinas - Google Patents

Aumento de la fertilidad en especies bovinas

Info

Publication number
UY37346A
UY37346A UY0001037346A UY37346A UY37346A UY 37346 A UY37346 A UY 37346A UY 0001037346 A UY0001037346 A UY 0001037346A UY 37346 A UY37346 A UY 37346A UY 37346 A UY37346 A UY 37346A
Authority
UY
Uruguay
Prior art keywords
fertility
increase
bovine species
bovine
species
Prior art date
Application number
UY0001037346A
Other languages
English (en)
Inventor
Jason Nickell
Daniel Keil
Warren
Gerhardus Martinu OLDE RIEKERINK Richard
Terry Settje
Leland Vickers
Stuart Nibbelink
Albert Abraham
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of UY37346A publication Critical patent/UY37346A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a composiciones y métodos de inmunomodulación que son eficaces para aumentar el porcentaje de concepción en vacas.
UY0001037346A 2016-07-26 2017-07-26 Aumento de la fertilidad en especies bovinas UY37346A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662366772P 2016-07-26 2016-07-26

Publications (1)

Publication Number Publication Date
UY37346A true UY37346A (es) 2018-02-28

Family

ID=59700165

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037346A UY37346A (es) 2016-07-26 2017-07-26 Aumento de la fertilidad en especies bovinas

Country Status (21)

Country Link
US (1) US10933131B2 (es)
EP (1) EP3490598A1 (es)
JP (1) JP2019525935A (es)
KR (1) KR102473370B1 (es)
CN (1) CN109689095B (es)
AR (1) AR109167A1 (es)
AU (1) AU2017301528A1 (es)
BR (1) BR112019001599A2 (es)
CA (1) CA3031778A1 (es)
CL (1) CL2019000185A1 (es)
CO (1) CO2019000724A2 (es)
CR (1) CR20190037A (es)
DO (1) DOP2019000018A (es)
IL (1) IL264380A (es)
MX (1) MX2019001126A (es)
NZ (1) NZ750181A (es)
PE (1) PE20190566A1 (es)
SG (1) SG11201900710YA (es)
TW (1) TWI759317B (es)
UY (1) UY37346A (es)
WO (1) WO2018022583A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102514899B1 (ko) * 2022-03-04 2023-03-29 경북대학교 산학협력단 암소 번식 능력 개선용 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
AP1775A (en) * 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
AU2002953015A0 (en) 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
AU2005271247A1 (en) 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free DNA vaccines
PE20120903A1 (es) 2009-05-14 2012-08-01 Bayer Ip Gmbh Respuesta inmunitaria reforzada en especies aviares
DK2654785T3 (da) * 2010-12-22 2019-06-24 Bayer Ip Gmbh Forøget immunrespons hos kvægracer
CA2820499A1 (en) * 2013-06-18 2014-12-18 Bayer Intellectual Property Gmbh Enhanced immune response in bovine species
RU2530520C1 (ru) * 2013-08-02 2014-10-10 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечернозёмной зоны Российской Федерации Российской академии сельскохозяйственных наук Средство для оптимизации воспроизводительной функции коров
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
US20190233825A1 (en) 2015-06-26 2019-08-01 Bayer Animal Health Gmbh Methods of modulating cytosolic dna surveillance molecules
CA2994039A1 (en) 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
AU2016302436B2 (en) 2015-07-31 2022-03-03 Bayer Animal Health Gmbh Enhanced immune response in porcine species

Also Published As

Publication number Publication date
CN109689095B (zh) 2023-10-03
AR109167A1 (es) 2018-11-07
PE20190566A1 (es) 2019-04-22
DOP2019000018A (es) 2019-07-31
BR112019001599A2 (pt) 2019-10-01
IL264380A (en) 2019-02-28
CO2019000724A2 (es) 2019-02-08
EP3490598A1 (en) 2019-06-05
MX2019001126A (es) 2019-08-14
AU2017301528A1 (en) 2019-02-14
SG11201900710YA (en) 2019-02-27
JP2019525935A (ja) 2019-09-12
KR102473370B1 (ko) 2022-12-05
NZ750181A (en) 2023-02-24
CN109689095A (zh) 2019-04-26
TWI759317B (zh) 2022-04-01
CA3031778A1 (en) 2018-02-01
US20190388538A1 (en) 2019-12-26
WO2018022583A1 (en) 2018-02-01
TW201817427A (zh) 2018-05-16
CR20190037A (es) 2019-05-16
CL2019000185A1 (es) 2019-06-28
US10933131B2 (en) 2021-03-02
KR20190032434A (ko) 2019-03-27

Similar Documents

Publication Publication Date Title
CL2018001368A1 (es) Composiciones que comprenden cepas bacterianas
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CO2018008707A2 (es) Inhibidores de la proteína quinasa 1 que interactúa con el receptor
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
PE20180266A1 (es) Composiciones que comprenden cepas bacterianas
BR112018009213A2 (pt) composições compreendendo cepas bacterianas
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
BR112017009623A2 (pt) composição de limpeza
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2018000451A1 (es) Composiciones de micropartículas que comprenden saflufenacil
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
ECSP19090645A (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
CL2018001788A1 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer.
CL2018003026A1 (es) Loci genéticos asociados con una mayor fertilidad en el maíz (divisional de la solicitud n° 2071-2016).
CL2018003377A1 (es) Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
MX2020004748A (es) Composiciones y metodos para mejorar el uso de fosforo y calcio de la dieta en animales.
CO2019000724A2 (es) Aumento de la fertilidad en especies bovinas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230626